/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Headquartered in Thousand Oaks, California, Amgen Inc. (AMGN) is a renowned player in the biotechnology industry. Valued at $179.1 billion by market cap, the company has a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology, and neuroscience markets.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and AMGN fits right into that category. Amgen is a leader in the biopharmaceutical industry, advancing healthcare through innovative research and a strong portfolio that includes flagship drugs like Epogen, Aranesp, and Enbrel. Besides, the October 2023 acquisition of Horizon Therapeutics for $27.8 billion has enhanced its oncology portfolio with Kyprolis, furthering its commitment to innovative therapies.